← Back to Search

Monoclonal Antibodies

Monoclonal Antibody Therapy for Small Cell Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cardiovascular: Ejection fraction at least 50%

Histologically or cytologically confirmed small cell lung cancer (SCLC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test if monoclonal antibody therapy can help patients with small cell lung cancer that has come back or hasn't responded to treatment.

Who is the study for?

This trial is for adults over 18 with small cell lung cancer that's come back or hasn't responded to treatment. They should have had chemotherapy, possibly with radiotherapy, and be generally healthy otherwise. No brain metastases, serious liver issues, or active infections like hepatitis B/C or HIV are allowed. Participants must not be pregnant and agree to use contraception.Check my eligibility

What is being tested?

The study is testing the effectiveness of a monoclonal antibody therapy in patients with relapsed or refractory small cell lung cancer. This phase I trial aims to see how well this therapy targets and kills cancer cells while sparing normal ones.See study design

What are the potential side effects?

Monoclonal antibodies might cause immune reactions leading to inflammation in various organs, allergic responses during infusion into the bloodstream, fatigue due to immune system activation, potential blood disorders from bone marrow effects, and increased risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My heart's pumping ability is normal or above.

Select...

My lung cancer diagnosis was confirmed through lab tests.

Select...

My lung function tests show at least 60% normal for FEV1 and FVC, and at least 50% for DLCO.

Select...

My cancer can be measured by tests.

Select...

My cancer shows high CEA levels or less than 25% bone marrow tumor involvement.

Select...

My liver functions are within normal limits and I don't have hepatitis B or C.

Select...

My kidney function is normal, and I don't have issues controlling my urine.

Select...

I've had chemotherapy and, if needed, specific chest radiation.

Select...

My cancer has worsened after receiving radiotherapy.

Select...

I do not have any active cancer spread to my brain.

Select...

I am 18 years old or older.

Select...

I can take care of myself and perform normal activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 12Eligibility criteria met

Find a Location

Who is running the clinical trial?

Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyLead Sponsor

9 Previous Clinical Trials

123 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,651 Previous Clinical Trials

40,932,930 Total Patients Enrolled

Jack D. Burton, MDStudy ChairGarden State Cancer Center at the Center for Molecular Medicine and Immunology

8 Previous Clinical Trials

114 Total Patients Enrolled

Media Library

Monoclonal Antibody Therapy (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00006347 — Phase 1

Lung Cancer Clinical Trial 2023: Monoclonal Antibody Therapy Highlights & Side Effects. Trial Name: NCT00006347 — Phase 1

Monoclonal Antibody Therapy (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006347 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this technique gained the endorsement of the FDA?

"The safety rating given to this particular treatment was 1 due to insufficient clinical evidence available at the Phase 1 level."

Answered by AI

Are there any remaining positions available for this clinical trial?

"The information on clinicaltrials.gov reveals that this experiment is no longer recruiting individuals as the last edit was made in February 2009. Despite its cessation of recruitment, there are 1,707 other trials enrolling patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

2000. "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006347.

All > Lung > Sclc